343 related articles for article (PubMed ID: 21125679)
1. The GIST paradigm: lessons for other kinase-driven cancers.
Antonescu CR
J Pathol; 2011 Jan; 223(2):251-61. PubMed ID: 21125679
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
3. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
4. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
5. Imatinib treatment for gastrointestinal stromal tumour (GIST).
Lopes LF; Bacchi CE
J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
Wang CM; Huang K; Zhou Y; Du CY; Ye YW; Fu H; Zhou XY; Shi YQ
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1065-71. PubMed ID: 20043176
[TBL] [Abstract][Full Text] [Related]
8. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
9. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
Lasota J; Miettinen M
Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
[TBL] [Abstract][Full Text] [Related]
10. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
11. KIT mutations in GIST.
Fletcher JA; Rubin BP
Curr Opin Genet Dev; 2007 Feb; 17(1):3-7. PubMed ID: 17208434
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
Gounder MM; Maki RG
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA
J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
16. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
17. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis and management of gastrointestinal stromal tumors.
Bayraktar UD; Bayraktar S; Rocha-Lima CM
World J Gastroenterol; 2010 Jun; 16(22):2726-34. PubMed ID: 20533592
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
20. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
Miranda C; Nucifora M; Molinari F; Conca E; Anania MC; Bordoni A; Saletti P; Mazzucchelli L; Pilotti S; Pierotti MA; Tamborini E; Greco A; Frattini M
Clin Cancer Res; 2012 Mar; 18(6):1769-76. PubMed ID: 22282465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]